Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Hyun-Woo ChoiDepartment of Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju 61496, Republic of Korea.ORCID 0000-0002-9438-1603
Yoo-Ree KangLaboratory Medicine Center, SD Medical Research Institute, Yongin 17013, Republic of Korea.ORCID 0009-0009-0577-3305
Eun-Soon SonMicrobiology Research Section, International Tuberculosis Research Center, Changwon 51755, Republic of Korea.ORCID 0000-0003-1732-1938
Kyungsik ChoiLaboratory Medicine Center, Korea National Tuberculosis Association, Seoul 06763, Republic of Korea.ORCID 0009-0005-7493-1996
Myungsun ChoLaboratory Medicine Center, Korea National Tuberculosis Association, Seoul 06763, Republic of Korea.ORCID 0009-0001-8989-1430
Young Jin KimDepartment of Laboratory Medicine, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul 02447, Republic of Korea.ORCID 0000-0001-8182-2433
Seo A LeeDepartment of Biomedical Sciences, Graduate School of Chonnam National University, Gwangju 61186, Republic of Korea.
Jin Young LeeLaboratory Medicine Center, SD Medical Research Institute, Yongin 17013, Republic of Korea.ORCID 0009-0008-7496-6111
Jee Hey KimLaboratory Medicine Center, SD Medical Research Institute, Yongin 17013, Republic of Korea.ORCID 0009-0000-1048-3745
Seon Joo KangLaboratory Medicine Center, SD Medical Research Institute, Yongin 17013, Republic of Korea.ORCID 0009-0008-2391-2121
Seung-Jung KeeDepartment of Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju 61496, Republic of Korea.ORCID 0000-0001-9708-5837
Jong Seok LeeMicrobiology Research Section, International Tuberculosis Research Center, Changwon 51755, Republic of Korea.ORCID 0000-0002-4340-9856
Hee Joo LeeLaboratory Medicine Center, SD Medical Research Institute, Yongin 17013, Republic of Korea.ORCID 0000-0001-8117-5512
Funding
National Research Foundation of Korea NRF-2023R1A2C1005947
6 · The paper itself
Abstract
Multidrug-resistant tuberculosis is a major global health concern. Newer agents, including bedaquiline (BDQ), delamanid (DLM), pretomanid (PMD), and linezolid (LZD), are essential for treatment; however, the resistance mechanisms of these drugs remain poorly understood in South Korea. This study aimed to investigate correlations between phenotypic and genotypic resistance to these drugs using 49 clinical
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Whole-Genome Sequencing and Phenotypic Drug Susceptibility Testing of Bedaquilin, Delamanid, Pretomanid, and Linezolid in Drug-Resistant · full record | OpenQuestion